Angiotensin converting enzyme (ACE) activity levels in insulin-independent diabetes mellitus and effect of ACE levels on diabetic patients with nephropathy

Cell Biochemistry and Function

Volumn 18, Issue 1, 2000, Pages 23-28

  Üstündaǧ, Bilal ^a   Canatan, Halit ^a   Çinkilinç, Nadire ^a   Halifeoǧlu, Ihsan ^a   Bahçecioǧlu, I Halil ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

Angiotensin converting enzyme (ACE); Diabetes mellitus (DM); Nephropathy

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ELECTROLYTES; FEMALE; HEMOGLOBIN A; HUMANS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A;

EID: 0343882010     PISSN: 02636484     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0844(200001/03)18:1<23::AID-CBF843>3.0.CO;2-0     Document Type: Article

References (31)

1. Welsch, C., Grima, M., Giesen, E. M., Helwig, J. J., Barthelmebs, M., Coquard, C. and Imbs, J. L. (1989). Assay of tissue angiotensin converting enzyme. J. Cardiovasc. Pharmacol., 14, 26-31.
2. Joseph, E. B. and Sandra, S. (1993). Studies on zinc and angiotensin converting enzyme. Clin. Chim. Acta, 217, 213-216.
3. Colin, I. J., Bruno, F. and Karin, J. (1993). Intrarenal renin angiotensin system in renal physiology and pathophysiology. Kid. Internat., 44, 59-63.
4. Allen, T. J., Cao, Z., Youssef, S., Hulthen, U. L. and Cooper, M. E. (1997). Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies. Diabetes, 46, 1612-1618.
5. Feman, S. S., Mericle, R. A., Reed, G.W., May J. M. and Workman, R. J. (1993). Serum angiotensin converting enzyme in diabetic patients. American J. Med. Sci., 305, 280-284.
6. De Cotret, P. R. (1998). Relationships among diabetes, microalbuminuria and ACE inhibition. J. Cardiovasc. Pharmacol., 32, 9-17.
7. Kikkawa, R., Tagawa, M., Isono, M., Isshiki, K. and Haneda, M. (1997). Mechanism of the progression of diabetic nephropathy to renal failure. Kid. Internat., 62, 39-40.
8. Miyauchi, E., Hosojima, H. and Morimoto, S. (1995). Urinary angiotensin converting enzyme activity in type 2 diabetes mellitus: its relationship to diabetic nephropathy. Acta Diabetol., 32, 193-197.
9. Holmquist, B., Bunning, P. and Riordan, J. F. (1979). A continuous spectrophotometric assay for angiotensin converting enzyme. Anal. Biochem., 95, 540.
10. Brownlee, M. and Cerami, A. (1981). The biochemistry of the complications of diabetes mellitus. Ann. Rev. Biochem., 50, 385-432.
11. Mogensen, C. E. (1996). Diabetic complications and early treatment using ACE inhibitors: Concluding remarks. J. Diabet. Complicat., 10, 151-153.
12. Hostetter, T. H. (1991). Diabetic nephropathy. In: The Kidney, (Brenner, B. M. and Rector, F. C. eds). W. B. Saunders: Philadelphia, 1964-1727.
13. Freire, M. B., Van Dijk, D. J., Erman, A., Boner, G., Warram, J. H. and Krolewski, A. S. (1998). DNA polymorphisms in the ACE gene, serum ACE activity and the risk of nephropathy in insulin-dependent diabetes mellitus. Nephrol. Dialy. Transplant, 13, 2553-2558.
14. Sen, G. C., Thekkumkara, T. J. and Kumar, R. S. (1990). Angiotensin converting enzyme: structural relationship of the testicular and pulmonary forms. J. Cardiovasc. Pharmacol., 16, 14-18.
15. Berecek, K. H. and Zhang, L. (1995). Biochemistry and cell biology of angiotensin converting enzyme (ACE) activity and converting enzyme inhibitors. Adv. Exp. Med. Biol., 377, 141-168.
16. Valentovic, M. A., Elliot, C. W. and Ball, J. G. (1987). The effect of streptozotocin-induced diabetes and insulin treatment on angiotensin converting enzyme activity. Res. Commun. Chem. Pathol. Pharmacol., 58, 27-39.
17. Allen, T. J., Hulthen, U. L., Rumble, J. R., Jasik, M. and Cooper, M. E. (1995). Diabetic vascular hypertrophy and albuminuria: effect of antiotensin converting enzyme inhibition. J. Diabet. Complicat., 9, 318-322.
18. Isogai, S., Kameyama, M., Iso, K. and Yoshino, G. (1998). Protective effects of small doses of captopril on the reduction of glomerular basement membrane anionic sites in spontaneous hypertensive rats with streptozotocin-induced diabetes. J. Diabet. Complicant., 12, 170-175.
19. Erman, A . Van Dijk, D. J., Chen-Gal, B., Giler, I. D., Rosenfeld, J. B. and Boner, G. (1993). Angiotensin converting enzyme activity in the serum, lung and kidney of diabetic rats. Eur. J. Clin. Invest., 23, 615-20.
20. Parving, H. H. (1998). Benefits and cost of antihypertensive treatment in incipient and overt diabetic nephropathy. J. Hyperten., 16(Suppl.), 99-101.
21. Mogensen, C. E. (1997). How to protect the kidney in diabetic patients: with special reference to IDDM. Diabetes, 46, 104-111.
22. Üstündaǧ, B., Çay, M., Naziroglu, M., Dilsiz, N., Crabbe, M. J. C. and Ilhan, N. (1999). The study of reninangiotensin-aldosterone in experimental diabetes mellitus. Cell Biochem. Funct., in press.
23. Üstündaǧ, B., Çay, M., Özercan, İ. H., Naziroǧlu, M. and İlhan, N. (1998). Angiotensin converting enzyme activity in the serum, lung, liver and kidney in streptozotocin-induced diabetic rats and diabetic nephropathy. Turk. J. Med. Sci., 28(3), 231-239.
24. Bangstad, H. J., Qsterby, R., Dahl, J., Hartman, A., Berg, K. S. and Lanssen, K. F. (1993). Glomerular basement membrane thickening and expansion are retarded by improved blood glucose control. EASD 29th Annual Meeting. İstanbul, A62 (Abstract), 234.
25. Bakris, G. and White, D. (1997). Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy. J. Hum. Hyperten., 11, 35-38.
26. UKPDS 39. UK Prospective Diabetes Study Group (1998). Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. Brit. Med. V., 317(7160), 713-720.
27. UKPDS 38. UK Prospective Diabetes Study Group (1998). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. Brit. Med. J., 317(7160), 703-713.
28. UKPDS 40. UK Prospective Diabetes Study Group (1998). Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes. Brit. Med. J., 317(7160), 720-726.
29. UKPDS 34. UK Prospective Diabetes Study (UKPDS) Group (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet. 352(9131), 854-865.
30. UKPDS 33. UK Prospective Diabetes Study (UKPDS) Group (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet, 352(9131), 837-853.
31. Szelachowska, M., Kretowski, A. and Zdrojewicz, Z. (1996). The increased activity of angiotensin converting enzyme in patients with diabetes and nephropathy. Horm. Metab. Res., 28, 250-251.